Cortiana V, Vallabhaneni H, Gambill J, Nadar S, Itodo K, Park C
Cancers (Basel). 2024; 16(16).
PMID: 39199619
PMC: 11352325.
DOI: 10.3390/cancers16162848.
Riviere D, van den Boezem P, Besselink M, van Laarhoven C, Kooby D, Vollmer C
Cochrane Database Syst Rev. 2024; 7():CD014017.
PMID: 39056402
PMC: 11274036.
DOI: 10.1002/14651858.CD014017.
Wang J, Lyu S, Cui S, Huang J, Wang H, Hu B
Int J Surg. 2024; 111(1):9-19.
PMID: 38995182
PMC: 11745578.
DOI: 10.1097/JS9.0000000000001944.
He J, Lv N, Yang Z, Luo Y, Zhong W, Wu C
Int J Surg. 2024; 110(6):3900-3909.
PMID: 38935819
PMC: 11175811.
DOI: 10.1097/JS9.0000000000001313.
Muaddi H, Kearse L, Warner S
Curr Oncol. 2024; 31(4):2260-2273.
PMID: 38668070
PMC: 11049254.
DOI: 10.3390/curroncol31040167.
Stereotactic body radiotherapy for pancreatic cancer - A systematic review of prospective data.
Shouman M, Fuchs F, Walter F, Corradini S, Westphalen C, Vornhulz M
Clin Transl Radiat Oncol. 2024; 45:100738.
PMID: 38370495
PMC: 10873666.
DOI: 10.1016/j.ctro.2024.100738.
Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival in Pancreatic Cancer.
Vehvilainen S, Kuuliala A, Udd M, Nurmi A, Peltola K, Haglund C
Ann Surg Oncol. 2023; 31(4):2621-2631.
PMID: 38153645
PMC: 10908635.
DOI: 10.1245/s10434-023-14793-6.
Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.
Pedrazzoli S
J Clin Med. 2023; 12(20).
PMID: 37892599
PMC: 10607532.
DOI: 10.3390/jcm12206461.
Failure of a Multi-Centric Clinical Trial Investigating Neoadjuvant Radio-Chemotherapy in Resectable Pancreatic Carcinoma (NEOPA-NCT01900327)-Which Lessons Are Learnt?.
Tachezy M, Gebauer F, Yekebas E, Izbicki J
Cancers (Basel). 2023; 15(17).
PMID: 37686537
PMC: 10487154.
DOI: 10.3390/cancers15174262.
Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
Chen E, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K
Cancer Med. 2023; 12(12):12986-12995.
PMID: 37132281
PMC: 10315770.
DOI: 10.1002/cam4.5971.
Validation of a Resectability Scoring System for Prediction of Pancreatic Adenocarcinoma Surgical Outcomes.
Toesca D, Susko M, von Eyben R, Baclay J, Pollom E, Jeffrey R
Ann Surg Oncol. 2023; 30(6):3479-3488.
PMID: 36792768
DOI: 10.1245/s10434-023-13120-3.
Nine-year survival of a 60-year-old woman with locally advanced pancreatic cancer under repeated open approach radiofrequency ablation: A case report.
Zhang J, Ding J, Zhou Y, Jing X
World J Clin Cases. 2022; 10(32):11845-11852.
PMID: 36405299
PMC: 9669842.
DOI: 10.12998/wjcc.v10.i32.11845.
Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma Is Associated With Limited Lymph Node Yield but Improved Ratio.
Barrak D, Villano A, Moslim M, Hopkins S, Lefton M, Ruth K
J Surg Res. 2022; 280:543-550.
PMID: 36096019
PMC: 9631810.
DOI: 10.1016/j.jss.2022.08.002.
Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study.
Stevens L, Brown Z, Zeh R, Monsour C, Wells-Di Gregorio S, Santry H
World J Gastrointest Oncol. 2022; 14(6):1175-1186.
PMID: 35949220
PMC: 9244990.
DOI: 10.4251/wjgo.v14.i6.1175.
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
Katz M, Shi Q, Meyers J, Herman J, Chuong M, Wolpin B
JAMA Oncol. 2022; 8(9):1263-1270.
PMID: 35834226
PMC: 9284408.
DOI: 10.1001/jamaoncol.2022.2319.
Total neoadjuvant therapy is associated with improved overall survival and pathologic response in pancreatic adenocarcinoma.
Villano A, OHalloran E, Goel N, Ruth K, Barrak D, Lefton M
J Surg Oncol. 2022; 126(3):502-512.
PMID: 35476892
PMC: 9340441.
DOI: 10.1002/jso.26906.
Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Schreiber L, Zeh R, Monsour C, Ejaz A, Tsung A, Pawlik T
HPB (Oxford). 2021; 24(6):833-840.
PMID: 34764009
PMC: 9035472.
DOI: 10.1016/j.hpb.2021.10.010.
Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma.
Sebastian N, Webb A, Merrell K, Koay E, Wolfe A, Zhang L
Cancers (Basel). 2021; 13(20).
PMID: 34680317
PMC: 8534163.
DOI: 10.3390/cancers13205168.
Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study.
Servetto A, Santaniello A, Napolitano F, Foschini F, Marciano R, Mozzillo E
Cancers (Basel). 2021; 13(19).
PMID: 34638422
PMC: 8508515.
DOI: 10.3390/cancers13194939.
Pancreatic Cancer: "Whether to Cross the Border"?.
Kurdia K, Kapoor V
Indian J Surg Oncol. 2021; 12(2):235-237.
PMID: 34295062
PMC: 8272748.
DOI: 10.1007/s13193-021-01341-5.
